JP2017504623A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017504623A5 JP2017504623A5 JP2016546835A JP2016546835A JP2017504623A5 JP 2017504623 A5 JP2017504623 A5 JP 2017504623A5 JP 2016546835 A JP2016546835 A JP 2016546835A JP 2016546835 A JP2016546835 A JP 2016546835A JP 2017504623 A5 JP2017504623 A5 JP 2017504623A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- loh
- parp inhibitor
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 28
- 201000011510 cancer Diseases 0.000 claims description 23
- 239000012661 PARP inhibitor Substances 0.000 claims description 15
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 206010033128 Ovarian cancer Diseases 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 102000036365 BRCA1 Human genes 0.000 claims description 4
- 108700020463 BRCA1 Proteins 0.000 claims description 4
- 101150072950 BRCA1 gene Proteins 0.000 claims description 4
- 102000052609 BRCA2 Human genes 0.000 claims description 4
- 108700020462 BRCA2 Proteins 0.000 claims description 4
- 101150008921 Brca2 gene Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 2
- 230000002939 deleterious effect Effects 0.000 claims description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928326P | 2014-01-16 | 2014-01-16 | |
| US61/928,326 | 2014-01-16 | ||
| US201462004424P | 2014-05-29 | 2014-05-29 | |
| US62/004,424 | 2014-05-29 | ||
| US201462039516P | 2014-08-20 | 2014-08-20 | |
| US62/039,516 | 2014-08-20 | ||
| US201462076165P | 2014-11-06 | 2014-11-06 | |
| US62/076,165 | 2014-11-06 | ||
| PCT/US2015/011413 WO2015108986A1 (en) | 2014-01-16 | 2015-01-14 | Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017504623A JP2017504623A (ja) | 2017-02-09 |
| JP2017504623A5 true JP2017504623A5 (enExample) | 2018-02-22 |
| JP6663350B2 JP6663350B2 (ja) | 2020-03-11 |
Family
ID=53543398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546835A Expired - Fee Related JP6663350B2 (ja) | 2014-01-16 | 2015-01-14 | ヘテロ接合性の喪失を示す乳癌または卵巣癌の患者を治療するためのｐａｒｐ阻害剤の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180163271A1 (enExample) |
| EP (1) | EP3094752A4 (enExample) |
| JP (1) | JP6663350B2 (enExample) |
| CN (1) | CN105917007A (enExample) |
| WO (1) | WO2015108986A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2704303T3 (es) | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| CA2839210A1 (en) | 2011-06-17 | 2012-12-20 | Myriad Genetics, Inc. | Methods and materials for assessing allelic imbalance |
| EP3660161B1 (en) | 2011-12-21 | 2024-07-31 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP3415915B1 (en) | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA2867434C (en) | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| WO2015051302A1 (en) | 2013-10-04 | 2015-04-09 | Aptose Biosciences Inc. | Compositions and methods for treating cancers |
| EP4023765A1 (en) | 2013-12-09 | 2022-07-06 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
| ES2800673T3 (es) | 2014-08-15 | 2021-01-04 | Myriad Genetics Inc | Métodos y materiales para evaluar una deficiencia de recombinación homóloga |
| US20160160294A1 (en) * | 2014-12-08 | 2016-06-09 | Tesaro | Methods and materials for predicting response to niraparib |
| JP6763114B2 (ja) * | 2016-06-02 | 2020-09-30 | 国立大学法人 琉球大学 | オオフトモモ抽出物を含むｐａｒｐ阻害剤 |
| EP3478286B1 (en) * | 2016-06-29 | 2024-01-03 | Tesaro, Inc. | Methods of treating ovarian cancer |
| CN108201534A (zh) * | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种瑞卡帕布口服缓控释药物组合物及其用途 |
| TWI879716B (zh) * | 2017-05-09 | 2025-04-11 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| MA49144A (fr) | 2017-05-18 | 2020-03-25 | Tesaro Inc | Polythérapies pour le traitement du cancer |
| PL3688155T3 (pl) * | 2017-09-28 | 2023-09-11 | Immpact-Bio Ltd. | Uniwersalna platforma do wytwarzania hamującego chimerycznego receptora antygenowego (icar) |
| CA3076515A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
| MA50618A (fr) | 2017-10-06 | 2020-08-12 | Tesaro Inc | Polyrhérapies et leurs utilisations |
| JP2021501203A (ja) * | 2017-10-30 | 2021-01-14 | アプトース バイオサイエンシズ インコーポレイテッド | がん治療用のアリールイミダゾール |
| EP3703669B1 (en) * | 2017-11-01 | 2025-08-06 | Dana-Farber Cancer Institute, Inc. | Usp1 or uaf1 inhibitors for use in treating cancer |
| WO2019099736A1 (en) * | 2017-11-15 | 2019-05-23 | The Regents Of The University Of California | Methods of treating extrachromosomal dna expressing cancers |
| US10933069B2 (en) | 2018-01-05 | 2021-03-02 | Cybrexa 1, Inc. | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues |
| WO2019195443A1 (en) * | 2018-04-04 | 2019-10-10 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor |
| WO2020163170A1 (en) * | 2019-02-05 | 2020-08-13 | The Board Of Regents Of The University Of Texas System | Trapping-free parp inhibitors |
| PH12022550037A1 (en) | 2019-07-10 | 2023-04-12 | Cybrexa 3 Inc | Peptide conjugates of microtubule-targeting agents as therapeutics |
| EP3997093A1 (en) | 2019-07-10 | 2022-05-18 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| ES3014370T3 (en) | 2020-04-28 | 2025-04-22 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
| WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
| AU2022255809A1 (en) | 2021-04-08 | 2023-10-26 | Incozen Therapeutics Pvt. Ltd. | Inhibitors of poly(adp-ribose) polymerase |
| WO2025078404A1 (en) * | 2023-10-10 | 2025-04-17 | Vib Vzw | Methods of determining response of a tumor to dna-damaging agents or to agents inhibiting or impairing dna repair |
| CN118995870B (zh) * | 2024-06-27 | 2025-05-27 | 华中科技大学同济医学院附属同济医院 | PARP抑制剂Veliparib在筛除BRCA1杂合突变胚胎中的应用和方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009027650A1 (en) * | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| WO2011160063A2 (en) * | 2010-06-18 | 2011-12-22 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| ES2704303T3 (es) * | 2010-08-24 | 2019-03-15 | Dana Farber Cancer Inst Inc | Procedimientos para la predicción de una respuesta contra el cáncer |
| US8729048B2 (en) * | 2011-11-22 | 2014-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents |
| AU2012342562B2 (en) * | 2011-11-25 | 2017-02-23 | Nerviano Medical Sciences S.R.L. | 3-phenyl-isoquinolin-1(2H)-one derivatives as PARP-1 inhibitors |
| WO2013133876A1 (en) * | 2011-12-07 | 2013-09-12 | The Regents Of The University Of California | Biomarkers for prediction of response to parp inhibition in breast cancer |
| EP3660161B1 (en) * | 2011-12-21 | 2024-07-31 | Myriad Genetics, Inc. | Methods and materials for assessing loss of heterozygosity |
| EP3415915B1 (en) * | 2012-02-23 | 2024-10-23 | Children's Medical Center Corporation | Methods for predicting response to parp inhibitors |
| CA2867434C (en) * | 2012-06-07 | 2021-10-12 | Institut Curie | Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors |
-
2015
- 2015-01-14 CN CN201580004684.5A patent/CN105917007A/zh active Pending
- 2015-01-14 EP EP15737714.4A patent/EP3094752A4/en not_active Withdrawn
- 2015-01-14 US US15/104,684 patent/US20180163271A1/en not_active Abandoned
- 2015-01-14 JP JP2016546835A patent/JP6663350B2/ja not_active Expired - Fee Related
- 2015-01-14 WO PCT/US2015/011413 patent/WO2015108986A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017504623A5 (enExample) | ||
| Schlereth et al. | Characterization of the p53 cistrome–DNA binding cooperativity dissects p53's tumor suppressor functions | |
| Wang et al. | Identification of new susceptibility loci for gastric non-cardia adenocarcinoma: pooled results from two Chinese genome-wide association studies | |
| Rosmarin et al. | A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS | |
| Stroud et al. | Comprehensive analysis of silencing mutants reveals complex regulation of the Arabidopsis methylome | |
| Son et al. | Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma | |
| Bergsagel et al. | V. Molecular classification and risk stratification of myeloma | |
| Pandey et al. | Long noncoding RNAs and neuroblastoma | |
| Rebollo et al. | Epigenetic interplay between mouse endogenous retroviruses and host genes | |
| Couto et al. | Association between CLOCK, PER3 and CCRN4L with non-small cell lung cancer in Brazilian patients | |
| JP2019509739A5 (enExample) | ||
| JP2020521442A5 (enExample) | ||
| Toraih et al. | Precursor miR-499a variant but not miR-196a2 is associated with rheumatoid arthritis susceptibility in an Egyptian population | |
| Morrison et al. | The splice site variant rs11078928 may be associated with a genotype-dependent alteration in expression of GSDMB transcripts | |
| Iglesias-Platas et al. | Characterization of novel paternal ncRNAs at the Plagl1 locus, including Hymai, predicted to interact with regulators of active chromatin | |
| Østrup et al. | Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases | |
| Zha et al. | Association of miR-146a gene polymorphism at loci rs2910164 G/C, rs57095329 A/G, and rs6864584 T/C with susceptibility to Kawasaki disease in Chinese children | |
| Omrane et al. | Involvement of IL17A, IL17F and IL23R polymorphisms in colorectal cancer therapy | |
| Zhang et al. | Identification of sequence polymorphisms in the displacement loop region of mitochondrial DNA as a risk factor for renal cell carcinoma | |
| Galasso et al. | The rs1001179 SNP and CpG methylation regulate catalase expression in chronic lymphocytic leukemia | |
| Guo et al. | Association of genetic variations in FOXO3 gene with susceptibility to noise induced hearing loss in a Chinese population | |
| Giunti et al. | A microRNA profile of pediatric glioblastoma: The role of NUCKS1 upregulation | |
| Wei et al. | Integrated analysis of dosage effect lncRNAs in lung adenocarcinoma based on comprehensive network | |
| Lawi et al. | Two co-inherited SNPs of the telomerase reverse transcriptase (TERT) gene are associated with Iraqi patients with lung cancer | |
| Mao et al. | The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients |